A new hope for OsteoArthritic patients


Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (EASME).

2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission


2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission


2015 17th i-Lab “Créadev” BPI France


2013 15th “émergence” OSEO/BPI


2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.

Contact Info

Parc scientifique Biocitech
102 Avenue Gaston Roussel
Batiment Pasteur Secteur 2169
93230 Romainville - France

56 Boulevard de la Mission Marchand - 92400 Courbevoie France

Phone: +33 1 43 34 89 90

Mobile: +33 6 60 90 41 24

27 07, 2020

2020 – Regulaxis is proud to announce that we have successfully won the Grand Oral of K Startup Grand Challenge

July 27th, 2020|0 Comments

We are therefore sending Matthieu Chareyre, Chief Business Development Officer and in charge of our Global Industrial Operations for 3.5 months in Asia to accelerate the inception of Regulaxis affiliate over there, the ignition of our Asian clinical trials, meeting Asian investors and paving the ground for our regional licensees

Let’s go !

3 07, 2020

2019 – Vancouver, Canada – 15th World Congress of ICRS

July 3rd, 2020|0 Comments

Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.

“REG-O3 Chimeric Peptide combining Growth Hormone and Somatostatin sequences slows down Traumatic Knee Osteoarthritis Progression in Rat”
Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Yves Henrotin, Christelle Vêtu

14 05, 2019

2019 – Milan, Italy – “Outsourcing in Clinical Trials Europe”

May 14th, 2019|0 Comments


Regulaxis’ President and CEO Claude Carelli and the CSO Christelle Vêtu participated to the OCT conference in Europe, in Milan, Italy, on May 14-15.

Follow us to http://regulaxis.com/news/

2 05, 2019

2019 – Toronto, Canada – OARSI World Congress

May 2nd, 2019|0 Comments

REGULAXIS is at the 2019 OARSI conference in Toronto from 2nd-5th of May !

OARSI World Congress on Osteoarthritis: Doctor Christelle Vêtu, CSO and Strategic Business Advisor will present the latest results during the poster session : “Chimeric Peptide combining both Growth Hormone and Somatostatin Sequences (REG-O3) improves function and prevents cartilage degradation in rat […]

26 04, 2018

2018 – Liverpool – OARSI World Congress on Osteoarthritis

April 26th, 2018|0 Comments

REGULAXIS, a leader in peptide research and development, will presents its most recent preclinical data of REG-O3, an innovative chimeric peptide for the treatment of osteoarthritis of knee at the 2018 Osteoarthritis Research Society International World Congress (OARSI), to be held April 26-29, 2018 in Liverpool, UK.

9 04, 2018

2018 – Macau, China – 14th World Congress of ICRS

April 9th, 2018|0 Comments

Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.
“REG-O3, new chimeric peptides regulating IGF-1 pathway: significant therapeutic effect on ACLT rabbit model of osteoarthritis”
Raffaello PAOLINI, Rodrick MONTJEAN and Christelle VETU